Science For A Better Life - Bayer

Outlook: More consistent exploitation
of sustainability potential
In addition to the continuation of our activities in
the areas of supplier management and stakeholder
dialogue, we aim to more intensively concentrate
on the global exploitation of sustainability potential
in our subgroups in the next two years. Many
of our products in the HealthCare, CropScience
and MaterialScience subgroups already make a
valuable contribution to sustainable development.
Our goal for the next two years is to systematically
support and further develop products that have
strong potential through research collaborations
and partnerships. We hope this will enable us to
achieve good ratings from analysts and investors
for whom the future orientation of companies has
become a key factor. After all, another goal of Bayer
is to continue to be represented in sustainability
indices and funds.
Strategy and Management
Central milestones and targets on our road to becoming
a sustainable company are presented in
the table below. It describes the direction in which
we are headed through the year 2010.
2005 2006 by 2010
Directive on Health, Safety, Environment and
Quality (HSEQ) Audits
A global tuberculosis (TB) study program for
Bayer’s active substance moxifloxacin is
launched, together with the product development
partnership the TB Alliance.
Inclusion in the Climate Leadership Index of
the Carbon Disclosure Project
Bayer presented with the “Low Carbon Leaders
Award” by the climate protection organization
“The Climate Group” at the Climate Summit in
Montreal.
21
Bayer Sustainable Development Report 2005
Sustainable Development Policy See Sustainability Program, p. 84 et seq.
Launch of the Group­wide innovation initiative
“Triple­i”
Third Sustainable Development Report